Changes in DAS28-3–ESR at 6 months according to serotype (primary effectiveness population)
| Seropositive patients (n=559) | Seronegative patients (n=169) | |||||
|---|---|---|---|---|---|---|
| Rituximab | Alternative TNF inhibitor | p Value | Rituximab | Alternative TNF inhibitor | p Value | |
| All patients | −1.6 (0.3) | −1.2 (0.3) | 0.011 | −1.3 (0.4) | −1.1 (0.4) | 0.449 |
| Inefficacy | −1.9 (0.3) | −1.5 (0.4) | 0.021 | −0.5 (0.6) | −0.2 (0.7) | 0.472 |
| Intolerance | −0.5 (0.5) | −0.5 (0.5) | 0.997 | −2.1 (1.2) | −1.9 (1.3) | 0.815 |
Values are LS mean (SE).
Patient numbers (all/inefficacy/intolerance): seropositive, rituximab 331/253/74 and TNF inhibitor 228/171/51; seronegative, rituximab 74/58/15 and TNF inhibitor 95/65/28. LS means and p values were based on analysis of covariance models with change in outcome as the dependent variable and treatment group as the independent variable, with controls for baseline value on the outcome variable, and unbalanced baseline characteristics.
DAS28-3, Disease Activity Score in 28 joints excluding patient's global health component; ESR, erythrocyte sedimentation rate; LS, least squares; TNF, tumour necrosis factor.